BSVL now gets permission to conduct phase III clinical study of Ulinastatin for mild to moderate ARDS patients with COVID 19
Ulinastatin, a serine protease inhibitor forays to phase III clinical trials; an add on therapy for patients infected by COVID 19 with mild and moderate ARDS An increasing number of global research teams believe Ulinastatin…